## All 23andMe Board Members But CEO Resign Over No Adequate Buyout Offers **23andMe, a personal genomics and biotechnology company, announced today that all of its board members except CEO Anne Wojcicki have resigned following a failed attempt to sell the company.** The resignations come after months of negotiations with potential buyers, including GlaxoSmithKline and Pfizer. The offers that were made were not considered adequate by the board, and the company ultimately decided not to sell. **The departures of the board members is a significant blow to 23andMe, which has been struggling financially in recent years.** The company has laid off employees and closed offices in an effort to cut costs. In addition, the company has been facing increased competition from other companies in the personal genomics space, such as AncestryDNA and MyHeritage. **The company's future is now uncertain.** Wojcicki said in a statement that she is "committed to continuing to lead 23andMe and building on the progress we have made." However, it is unclear how the company will be able to move forward without the support of its board of directors. **The resignations of the board members is a reminder of the challenges facing 23andMe.** The company has a lot of potential, but it is also facing a number of challenges. It remains to be seen whether the company will be able to overcome these challenges and achieve long-term success.
Comments